Cabozantinib exhibits potent antitumor activity in colorectal cancer patient-derived tumor xenograft models via autophagy and signaling mechanisms

Anti-angiogenic therapy used in treatment of metastatic colorectal cancer (mCRC) inevitably succumbs to treatment resistance. Upregulation of MET may play an essential role to acquired anti-VEGF resistance. We previously reported that cabozantinib (XL184), an inhibitor of receptor tyrosine kinases (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Scott, Aaron J, Bagby, Stacey M, Yahn, Rachel, Huber, Kendra M, Serkova, Natalie J, Nguyen, Anna, Kim, Jihye, Thorburn, Andrew, Vogel, Jon, Quackenbush, Kevin S., Capasso, Anna, Schreiber, Anna, Blatchford, Patrick, Klauck, Peter J, Pitts, Todd M., Eckhardt, S. Gail, Messersmith, Wells
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6168336/
https://ncbi.nlm.nih.gov/pubmed/30026382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0131
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados